Drug class
Calcium sensitiser; inodilator and cardiac inotrope
Mechanism of action
Binds selectively to calcium-saturated cardiac troponin C, increasing myofilament sensitivity to calcium during systole without raising intracellular calcium. It also opens ATP-sensitive potassium channels in vascular smooth muscle, causing arterial and venous vasodilation; PDE3 inhibition may contribute at higher concentrations.
General use cases
- Short-term intravenous treatment of acute severe decompensation of chronic heart failure when conventional therapy is insufficient and inotropic support is considered appropriate; use requires specialist haemodynamic monitoring and is product/jurisdiction-specific
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
